{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T19:40:37Z","timestamp":1779910837114,"version":"3.53.1"},"reference-count":46,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2002,7,1]],"date-time":"2002-07-01T00:00:00Z","timestamp":1025481600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of the American Pharmaceutical Association (1996)"],"published-print":{"date-parts":[[2002,7]]},"DOI":"10.1331\/108658002763029580","type":"journal-article","created":{"date-parts":[[2003,6,17]],"date-time":"2003-06-17T12:53:18Z","timestamp":1055854398000},"page":"602-611","source":"Crossref","is-referenced-by-count":12,"title":["Insulin Therapy in Type 2 Diabetes"],"prefix":"10.1016","volume":"42","author":[{"given":"R.","family":"Keith Campbell","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr.","given":"John R.","family":"White","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1331\/108658002763029580_bb0010","series-title":"Medical Management of Type 2 Diabetes","author":"American Diabetes Association","year":"1998"},{"key":"10.1331\/108658002763029580_bb0015","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.2337\/diab.43.8.1066","article-title":"Banting Lecture: Insulin action, diabetogenes, and the cause of type II diabetes","volume":"43","author":"Kahn","year":"1994","journal-title":"Diabetes."},{"key":"10.1331\/108658002763029580_bb0020","first-page":"298","article-title":"Impaired B, cell function with chronic hyperglycemia: \"overworked B cell\" hypothesis","volume":"4","author":"Leahy","year":"1996","journal-title":"Diabetes Rev."},{"key":"10.1331\/108658002763029580_bb0025","doi-asserted-by":"crossref","first-page":"610","DOI":"10.2337\/diacare.13.6.610","article-title":"Glucose toxicity","volume":"13","author":"Rosetti","year":"1990","journal-title":"Diabetes Care."},{"key":"10.1331\/108658002763029580_bb0030","doi-asserted-by":"crossref","first-page":"85","DOI":"10.3810\/pgm.1997.02.159","article-title":"Insulin therapy in type II diabetes: who needs it, how much of it, and for how long?","volume":"101","author":"Skyler","year":"1997","journal-title":"Postgrad Med."},{"key":"10.1331\/108658002763029580_bb0035","doi-asserted-by":"crossref","first-page":"222","DOI":"10.2337\/diab.34.3.222","article-title":"The effect of insulin treatment on insulin secretion and insulin action in type II diabetes mellitus","volume":"34","author":"Garvey","year":"1985","journal-title":"Diabetes."},{"key":"10.1331\/108658002763029580_bb0040","doi-asserted-by":"crossref","first-page":"815","DOI":"10.2337\/diacare.15.7.815","article-title":"Onset of NIDDM occurs at least 4\u20137 yr before clinical diagnosis","volume":"15","author":"Harris","year":"1992","journal-title":"Diabetes Care."},{"key":"10.1331\/108658002763029580_bb0045","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1001\/archopht.1984.01040030405011","article-title":"Wisconsin Epidemiologic Study of Diabetic Retinopathy. III. Prevalence and risk of diabetic retinopathy when age at diagnosis is 30 or more years","volume":"102","author":"Klein","year":"1984","journal-title":"Arch Ophthalmol"},{"key":"10.1331\/108658002763029580_bb0050","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1001\/jama.281.21.2005","article-title":"Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS49). UK Prospective Diabetes Study (UKPDS) Group","volume":"281","author":"Turner","year":"1999","journal-title":"JAMA"},{"key":"10.1331\/108658002763029580_bb0055","series-title":"Overview of medications used to treat type 2 diabetes. In: Medications for the Treatment of Diabetes","author":"Campbell","year":"2000"},{"key":"10.1331\/108658002763029580_bb0060","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1056\/NEJM199309303291401","article-title":"The effect of intensive treatment of diabetes on the development and progression of long-term complications of insulin-dependent diabetes mellitus","volume":"329","author":"The Diabetes Control and Complications Trial Research Group","year":"1993","journal-title":"N Engl J Med."},{"key":"10.1331\/108658002763029580_bb0065","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/0168-8227(95)01064-K","article-title":"Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized, prospective 6-year study","volume":"28","author":"Ohkubo","year":"1995","journal-title":"Diabetes Res Clin Pract."},{"issue":"9131","key":"10.1331\/108658002763029580_bb0070","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/S0140-6736(98)07019-6","article-title":"Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS33)","volume":"352","author":"UK Prospective Diabetes Study (UKPDS) Group","year":"1998","journal-title":"Lancet."},{"issue":"9131","key":"10.1331\/108658002763029580_bb0075","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1016\/S0140-6736(98)07037-8","article-title":"Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS34)","volume":"352","author":"UK Prospective Diabetes Study (UKPDS) Group","year":"1998","journal-title":"Lancet."},{"issue":"7093","key":"10.1331\/108658002763029580_bb0080","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.1136\/bmj.314.7093.1512","article-title":"Prospective randomised study of intensive insulin treatment on long-term survival after acute myocardial infarction in patients with diabetes mellitus","volume":"314","author":"Malmberg","year":"1997","journal-title":"BMJ."},{"key":"10.1331\/108658002763029580_bb0085","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.2337\/diacare.23.9.1236","article-title":"Therapy focused on lowering postprandial glucose, not fasting glucose, may be superior for lowering HbAlc","volume":"23","author":"Bastyr","year":"2000","journal-title":"Diabetes Care."},{"key":"10.1331\/108658002763029580_bb0090","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1007\/s001250050617","article-title":"Risk factors for myocardial infarction and death in newly detected NIDDM: the Diabetes Intervention Study, 11-yearfollow-up","volume":"39","author":"Hanefeld","year":"1996","journal-title":"Diabetologia."},{"key":"10.1331\/108658002763029580_bb0095","doi-asserted-by":"crossref","first-page":"461","DOI":"10.2337\/diacare.14.6.461","article-title":"Insulin and cardiovascular disease: Paris Prospective Study","volume":"14","author":"Fontbomme","year":"1991","journal-title":"Diabetes Care."},{"issue":"9179","key":"10.1331\/108658002763029580_bb0100","first-page":"617","article-title":"Diabetes Epidemiology: Collaborative Analysis of Diagnostic Criteria in Europe","volume":"354","author":"Glucose tolerance and mortality: comparison of WHO and American Diabetes Association diagnostic criteria. The DECODE study group. European Diabetes Epidemiology Group","year":"1999","journal-title":"Lancet"},{"key":"10.1331\/108658002763029580_bb0105","doi-asserted-by":"crossref","first-page":"920","DOI":"10.2337\/diacare.22.6.920","article-title":"Impaired glucose tolerance is a risk factor for cardiovascular disease but not impaired fasting glucose","volume":"22","author":"Tominaga","year":"1999","journal-title":"The Funagata Diabetes Study. Diabetes Care."},{"key":"10.1331\/108658002763029580_bb0110","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1046\/j.1463-1326.1999.00015.x","article-title":"Early intensive insulin treatment for induction of long-term glycaemic control in type 2 diabetes","volume":"1","author":"Glaser","year":"1999","journal-title":"Diabetes Obes Metab."},{"key":"10.1331\/108658002763029580_bb0115","doi-asserted-by":"crossref","first-page":"37S","DOI":"10.1016\/0002-9343(91)90416-U","article-title":"Effect of 6-month gliclazide treatment on insulin release and sensitivity to endogenous insulin in NIDDM: role of initial continuous subcutaneous insulin infusion-induced normoglycemia","volume":"90","author":"Delia Casa","year":"1991","journal-title":"Am J Med."},{"key":"10.1331\/108658002763029580_bb0120","doi-asserted-by":"crossref","first-page":"738","DOI":"10.2337\/diabetes.48.4.738","article-title":"Hyperglycemia-induced beta cell apoptosis in pancreatic islets in Psammomys obesus during development of diabetes","volume":"48","author":"Donath","year":"1999","journal-title":"Diabetes."},{"key":"10.1331\/108658002763029580_bb0125","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1172\/JCI115989","article-title":"Prolonged exposure of human pancreatic islets to high glucose concentrations in vitro impairs the beta cell function","volume":"90","author":"Eizirik","year":"1992","journal-title":"J Clin Invest."},{"key":"10.1331\/108658002763029580_bb0130","doi-asserted-by":"crossref","first-page":"2805","DOI":"10.1172\/JCI119108","article-title":"Prolonged exposure of human beta cells to elevated glucose levels results in sustained cellular activation leading to a loss of glucose regulation","volume":"98","author":"Ling","year":"1996","journal-title":"J Clin Invest."},{"key":"10.1331\/108658002763029580_bb0135","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/BF01228297","article-title":"Increase in insulin response after treatment of overt maturity-onset diabetes is independent of the mode of treatment","volume":"18","author":"Kosaka","year":"1980","journal-title":"Diabetologia."},{"key":"10.1331\/108658002763029580_bb0140","doi-asserted-by":"crossref","first-page":"892","DOI":"10.2337\/diab.36.8.892","article-title":"Hyperglycemia decreases glucose uptake in type 1 diabetes","volume":"36","author":"Yki-Jarvinen","year":"1987","journal-title":"Diabetes."},{"key":"10.1331\/108658002763029580_bb0145","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.2337\/diacare.20.9.1353","article-title":"Induction of long-term glycemic control in newly diagnosed type 2 diabetic patients by transient intensive insulin treatment","volume":"20","author":"Ilkova","year":"1997","journal-title":"Diabetes Care."},{"key":"10.1331\/108658002763029580_bb0150","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1007\/BF00285334","article-title":"Different effects of insulin and oral antidiabetic agents on glucose and energy metabolism in type 2 (non-insulin-dependent) diabetes mellitus","volume":"32","author":"Groop","year":"1989","journal-title":"Diabetologia."},{"issue":"suppl 2","key":"10.1331\/108658002763029580_bb0155","first-page":"A3","article-title":"Pretranslational alterations in GLUT-4 gene expression in type 2 diabetes irrespective of control","volume":"34","author":"Yki-Jarvinen","year":"1991","journal-title":"Diabetologia."},{"key":"10.1331\/108658002763029580_bb0160","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1172\/JCI111153","article-title":"Improvement in in vitro insulin action after one month of insulin therapy in obese noninsulin-depen-dent diabetics. Measurements of glucose transport and metabolism, insulin binding, and lipolysis in isolated adipocytes","volume":"72","author":"Foley","year":"1983","journal-title":"J Clin Invest"},{"key":"10.1331\/108658002763029580_bb0165","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/S0889-8529(05)70268-1","article-title":"Current therapies for diabetes: insulins","volume":"26","author":"Burge","year":"1997","journal-title":"Endocrinol Metab Clin North Am."},{"key":"10.1331\/108658002763029580_bb0170","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.2337\/diacare.20.10.1539","article-title":"Modification of postprandial hyperglycemia with insulin lispro improves glucose control in patients with type 2 diabetes","volume":"20","author":"Feinglos","year":"1997","journal-title":"Diabetes Care."},{"key":"10.1331\/108658002763029580_bb0175","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1001\/archinte.1997.00440320157015","article-title":"Mealtimetreatmentwith insulin analogue improves postprandial hyperglycemia and hypoglycemia in patients with non-insulin-dependent diabetes mellitus","volume":"157","author":"Anderson","year":"1997","journal-title":"Arch Intern Med."},{"key":"10.1331\/108658002763029580_bb0180","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1345\/1542-6270(2000)034<1373:IAANRA>2.0.CO;2","article-title":"Insulin aspart: a new rapid-acting insulin analogue","volume":"34","author":"Setter","year":"2000","journal-title":"Ann Pharmacother."},{"key":"10.1331\/108658002763029580_bb0185","doi-asserted-by":"crossref","first-page":"801","DOI":"10.2337\/diacare.22.5.801","article-title":"Improved postprandial glycaemic control with insulin aspart\u2014a randomized, double-blind cross-over trial in type 1 diabetes mellitus","volume":"22","author":"Lindholm","year":"1999","journal-title":"Diabetes Care."},{"key":"10.1331\/108658002763029580_bb0190","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.2337\/diacare.21.11.1904","article-title":"Improved glycemic control with insulin aspart\u2014a multicenter randomized double-blind cross-overtrial in type 1 diabetes patients","volume":"21","author":"Home","year":"1998","journal-title":"Diabetes Care."},{"key":"10.1331\/108658002763029580_bb0195","first-page":"DA358","article-title":"Improved long-term blood glucose control with insulin aspart versus human insulin in people with type 1 diabetes","volume":"48","author":"Home","year":"1999","journal-title":"European Insulin Aspart Study Group. Diabetes."},{"key":"10.1331\/108658002763029580_bb0200","doi-asserted-by":"crossref","first-page":"639","DOI":"10.2337\/diacare.23.5.639","article-title":"Less hypoglycemia with insulin glargine in intensive insulin therapy for type 1 diabetes. U.S. Study Group of Insulin Glargine in Type 1 Diabetes","volume":"23","author":"Ratner","year":"2000","journal-title":"Diabetes Care"},{"key":"10.1331\/108658002763029580_bb0205","doi-asserted-by":"crossref","first-page":"631","DOI":"10.2337\/diacare.24.4.631","article-title":"Basal insulin therapy in type 2 diabetes: 28-week comparison of insulin glargine (HOE 901) and NPH insulin","volume":"24","author":"Rosenstock","year":"2001","journal-title":"Diabetes Care."},{"key":"10.1331\/108658002763029580_bb0210","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.2337\/diacare.23.11.1666","article-title":"A 16-week comparison of the novel insulin analogue insulin glargine (HOE 901) and NPH human insulin used with insulin lispro in patients with type 1 diabetes","volume":"23","author":"Raskin","year":"2000","journal-title":"Diabetes Care."},{"key":"10.1331\/108658002763029580_bb0215","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.2337\/diacare.22.8.1258","article-title":"Improved postprandial glycemic control during treatment with Humalog Mix25, a novel protamine-based insulin lispro formulation. Humalog Mix25 Study Group","volume":"22","author":"Roach","year":"1999","journal-title":"Diabetes Care"},{"key":"10.1331\/108658002763029580_bb0220","doi-asserted-by":"crossref","first-page":"440","DOI":"10.2337\/diab.46.3.440","article-title":"Insulin lispro in CSII: results of a double-blind crossover study","volume":"46","author":"Zinman","year":"1997","journal-title":"Diabetes."},{"key":"10.1331\/108658002763029580_bb0225","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1016\/S0095-4543(05)70140-8","article-title":"The use of insulin alone and in combination with oral agents in type 2 diabetes","volume":"26","author":"Buse","year":"1999","journal-title":"Primary Care."},{"key":"10.1331\/108658002763029580_bb0230","first-page":"58","article-title":"The pharmacologic reduction of blood glucose in patients with type 2 diabetes mellitus","volume":"16","author":"White","year":"1998","journal-title":"Clin Diabetes."},{"key":"10.1331\/108658002763029580_bb0235","unstructured":"Lantus [package insert]. Kansas City, Mo: Aventis Pharmaceuticals Inc; 2001. Available at: www.lanutus.com\/professional\/home.html. Accessed June 4, 2002."}],"container-title":["Journal of the American Pharmaceutical Association (1996)"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1086580215302321?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1086580215302321?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,3,20]],"date-time":"2019-03-20T15:31:50Z","timestamp":1553095910000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1086580215302321"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,7]]},"references-count":46,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2002,7]]}},"alternative-id":["S1086580215302321"],"URL":"https:\/\/doi.org\/10.1331\/108658002763029580","relation":{},"ISSN":["1086-5802"],"issn-type":[{"value":"1086-5802","type":"print"}],"subject":[],"published":{"date-parts":[[2002,7]]}}}